Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

Rocklatan® Evaluation

ClinicalTrials.gov ID: NCT05283395

Public ClinicalTrials.gov record NCT05283395. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Open-Label Rocklatan® (Netarsudil/Latanoprost Ophthalmic Solution) 0.02%/0.005% Evaluation of IOP Lowering Efficacy and Safety as Replacement of Current Medical Therapy Regimen for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension

Study identification

NCT ID
NCT05283395
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Aerie Pharmaceuticals
Industry
Enrollment
136 participants

Conditions and interventions

Conditions

Interventions

  • Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 27, 2022
Primary completion
Mar 21, 2023
Completion
Mar 21, 2023
Last update posted
Apr 2, 2024

2022 – 2023

United States locations

U.S. sites
21
U.S. states
11
U.S. cities
20
Facility City State ZIP Site status
North Valley Eye Medical Group Mission Hills California 91345
Visionary Eye Institute Newport Beach California 92663
California Eye Specialists Medical Group Pasadena California 91107
North Bay Eye Associates Petaluma California 94954
Shettle Eye Research Largo Florida 33773
Center For Sight Venice Florida 34285
Georgia Eye Partners Atlanta Georgia 30342
Coastal Research Associates LLC Roswell Georgia 30076
Tekwani Vision Center St Louis Missouri 63128
OCLI Vision Manhasset New York 11030
Mark J. Weiss, MD, Inc. Tulsa Oklahoma 74104
Scott & Christie and Associates, PC Cranberry Township Pennsylvania 16066
Advancing Vision Research Goodlettsville Tennessee 37072
VRF Eye Specialty Group Memphis Tennessee 38120
Total Eye Care, PA Memphis Tennessee 38199
Keystone Research Austin Texas 78731
Louis M. Alpern, M.D., M.P.H., P.A El Paso Texas 79902
Houston Eye Associates Houston Texas 77025
Emerson Clinical Research Institute Falls Church Virginia 22046
Vistar Eye Center Roanoke Virginia 24016
The Eye Centers of Racine and Kenosha Racine Wisconsin 53405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05283395, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 2, 2024 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05283395 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →